UBS Starts Abbvie (ABBV) at Neutral
Tweet Send to a FriendGet Alerts ABBV Hot Sheet
Price: $46.54 -1.34%
Rating Summary:
6 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 12
Rating Summary:
6 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 12
Trade ABBV Now!
Earlier, UBS initiated coverage on Abbvie (NYSE: ABBV) with a Neutral rating and $36 price target.
The firm comments, "Our thesis is three-fold: (1) Humira should be durable but competition from oral therapies and generics for now will remain a concern for investors. (2) Earnings in 2013/2014 will be held down by ~$2.5-3B sales hit from its lipid and HIV franchises going generic. (3) The late stage pipeline doesn’t kick in until 2015-16 and it’s still unclear how big its most important asset, the HCV franchise, will be given how quickly market dynamics are changing."
EPS estimates are $3.08 for 2013 and $3.20 for 2014. 5 year CAGRs are 1% for revenues and 2% for EPS.
For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.
Shares of Abbvie closed at $34.00 yesterday, with a 52 week range of $33.33-$35.45.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "Our thesis is three-fold: (1) Humira should be durable but competition from oral therapies and generics for now will remain a concern for investors. (2) Earnings in 2013/2014 will be held down by ~$2.5-3B sales hit from its lipid and HIV franchises going generic. (3) The late stage pipeline doesn’t kick in until 2015-16 and it’s still unclear how big its most important asset, the HCV franchise, will be given how quickly market dynamics are changing."
EPS estimates are $3.08 for 2013 and $3.20 for 2014. 5 year CAGRs are 1% for revenues and 2% for EPS.
For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.
Shares of Abbvie closed at $34.00 yesterday, with a 52 week range of $33.33-$35.45.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: BTIG Starts ING U.S (VOYA) at Buy, Shares 'Significantly Undervalued'
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- Citi Starts Taylor Morrison Home (TMHC) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBS, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
